This randomized phase III trial studies digital tomosynthesis mammography and digital mammography in screening patients for breast cancer. Screening for breast cancer with tomosynthesis mammography may be superior to digital mammography for breast cancer screening and may help reduce the need for additional imaging or treatment.
Eligibility
Sex
FEMALE
Min age
45 Years
Max age
74 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Women of childbearing potential must not be known to be pregnant or lactating
* Patients must be scheduled for, or have intent to schedule, a screening mammogram
* Patients must be able to tolerate digital breast tomosynthesis and full-field digital mammographic imaging required by protocol.
* Patients must be willing and able to provide a written informed consent
* Patients must not have symptoms or signs of benign or malignant breast disease (eg, nipple discharge, breast lump) warranting a diagnostic rather than a screening mammogram, and/or other imaging studies (eg, sonogram); patients with breast pain are eligible as long as other criteria are met
* Patients must not have had a screening mammogram within the last 11 months prior to date of randomization
* Patients must not have previous personal history of breast cancer including ductal carcinoma in situ
* Patients must not have breast enhancements (e.g., implants or injections)
* ANNUAL SCREENING REGIMEN ELIGIBILITY CHECK
* To be eligible for inclusion in the annual screening regimen one of the following three conditions must be met in addition to the eligibility criteria above:
* Patients are pre-menopausal; OR
* Post-menopausal aged 45-69 with any of the following three risks factors:
* Dense breasts (BIRADS density categories c-heterogeneously dense or d-extremely dense), or
* Family history of breast cancer (first degree relative with breast cancer), or, positive genetic testing for any deleterious genes that indicate an increased risk for breast cancer, or
* Currently on hormone therapy; OR
* Post-menopausal ages 70-74 with either of the following two risk factors:
* Dense breasts (BIRADS density categories c-heterogeneously dense or d-extremely dense), or
* Currently on hormone therapy
* Postmenopausal women are defined as those with their last menstrual period more than 12 months prior to study entry; for the purpose of defining menopausal status for women who have had surgical cessation of their periods, women who no longer have menses due to hysterectomy and oophorectomy will be considered postmenopausal; women who no longer have menses due to hysterectomy without oophorectomy will be considered premenopausal until age 52 and postmenopausal thereafter
* All other postmenopausal women are eligible for inclusion in the biennial screening regimen
* For those women who cannot be assigned to annual or biennial screening at the time of study entry and randomization because they are postmenopausal, have no family history or known deleterious breast cancer mutation, are not on hormone therapy AND have not had a prior mammogram, breast density will be determined by the radiologist?s recording of it at the time of interpretation of the first study screening examination, either DM or TM; for those who are randomized to TM, radiologists will assign BI-RADS density through review of the DM or synthetic DM portion of the TM examination; such women cannot be part of the planned stratification by screening frequency and are expected to represent far less than 1% of the Tomosynthesis Mammographic Imaging Screening Trial (TMIST) population
* Breast density will be determined by prior mammography reports, when available; all other risk factors used to determine patient eligibility for annual or biennial screening will be determined by subject self-report
Primary outcome measure(s)
Proportion of women diagnosed with an advanced breast cancer at any time during a period of 4.5 years from randomization, including the period of active screening and a period of follow up after the last screen — 4.5 years after last registration The cumulative proportions of participants experiencing the primary endpoint in the two study arms will be compared. The primary comparison of the two study arms will be approached from an Intent-to-Treat perspective and will be based on a two-sided test for comparing binomial proportions.
Trial sites (149)
Facility
City
Region
Status
University of Alabama at Birmingham Cancer Center
Birmingham
Alabama
Mobile Infirmary Medical Center
Mobile
Alabama
Banner-University Medical Center Phoenix
Phoenix
Arizona
University of Arizona College of Medicine Phoenix
Phoenix
Arizona
Valleywise Comprehensive Health Center - Phoenix
Phoenix
Arizona
Mayo Clinic Hospital in Arizona
Phoenix
Arizona
Scottsdale Medical Imaging Limited
Scottsdale
Arizona
University of Arkansas for Medical Sciences
Little Rock
Arkansas
Kern Radiology Medical Group Inc
Bakersfield
California
Los Angeles General Medical Center
Los Angeles
California
USC / Norris Comprehensive Cancer Center
Los Angeles
California
Kaiser Permanente-Modesto
Modesto
California
Zuckerberg San Francisco General Hospital
San Francisco
California
UCHealth University of Colorado Hospital
Aurora
Colorado
Penrose-Saint Francis Healthcare
Colorado Springs
Colorado
The Women's Imaging Center
Denver
Colorado
Radiology Imaging Associates
Englewood
Colorado
UCHealth Highlands Ranch Hospital
Highlands Ranch
Colorado
UCHealth Lone Tree Health Center
Lone Tree
Colorado
Helen F Graham Cancer Center
Newark
Delaware
MedStar Georgetown University Hospital
Washington D.C.
District of Columbia
University of Florida Health Science Center - Jacksonville
Jacksonville
Florida
Northside Hospital
Atlanta
Georgia
Northeast Georgia Medical Center Braselton
Braselton
Georgia
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
Savannah
Georgia
Queen's Medical Center
Honolulu
Hawaii
Saint Alphonsus Cancer Care Center-Boise
Boise
Idaho
Saint Luke's Cancer Institute - Boise
Boise
Idaho
Bromenn Lifecare Center
Bloomington
Illinois
John H Stroger Jr Hospital of Cook County
Chicago
Illinois
Carle at The Riverfront
Danville
Illinois
Carle on Fairchild
Danville
Illinois
Decatur Memorial Hospital
Decatur
Illinois
Carle Hoopeston Regional Health Center
Hoopeston
Illinois
Carle Physician Group-Mattoon/Charleston
Mattoon
Illinois
Bromenn Regional Medical Center
Normal
Illinois
Carle Cancer Center
Urbana
Illinois
Saint Mary Medical Center
Hobart
Indiana
Indiana University/Melvin and Bren Simon Cancer Center
Indianapolis
Indiana
The Community Hospital
Munster
Indiana
+ 109 more sites — see the full list on the official registry below.
More ECOG-ACRIN Cancer Research Group trials in Canada
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.